Global Blood Therapeutics (GBT) Stock Price, News & Analysis

Company Overview

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $68.49 to $68.49
• 50-Day Range: $68.07 to $68.49
• 52-Week Range: $21.65 to $73.02
• Volume: 74 shs
• Average Volume: 2.07 million shs
• Market Capitalization: $4.62 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GBT Stock Analysis - Frequently Asked Questions

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its quarterly earnings data on Thursday, November, 4th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.10) by $0.03. Global Blood Therapeutics's revenue was up 41.1% compared to the same quarter last year.

When did Global Blood Therapeutics IPO?

Global Blood Therapeutics (GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Meta Platforms (META), Intel (INTC), Bristol Myers Squibb (BMY) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GBT
• CIK: 1629137
• Web: www.gbt.com
• Phone: (650) 741-7700
• Fax: N/A
• Employees: 457
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($5.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$303.09 million
• Net Margins: -137.30%
• Pretax Margin: -137.01%
• Return on Equity: -170.37%
• Return on Assets: -39.24%

Debt

• Debt-to-Equity Ratio: 4.92
• Current Ratio: 6.88
• Quick Ratio: 6.17

Sales & Book Value

• Annual Sales: $194.75 million
• Price / Sales: 23.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.05 per share
• Price / Book: 22.46

Miscellaneous

• Outstanding Shares: 67,476,000
• Free Float: 64,170,000
• Market Cap: $4.62 billion
• Optionable: Optionable
• Beta: 0.45